Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Ntombifuthi Princess Ngubane & Brenda Zola De Gama. (2023) A quantitative evaluation of traditional health practitioners’ perspectives on mental disorders in KwaZulu-Natal: knowledge, diagnosis, and treatment practices. Journal of Spirituality in Mental Health 0:0, pages 1-21.
Read now
Read now
Seth C. Hopkins, Robert Lew, Courtney Zeni & Kenneth S. Koblan. (2023) Challenges in the clinical development of non-D2 compounds for schizophrenia. Current Medical Research and Opinion 39:3, pages 467-471.
Read now
Read now
Awais Aftab & Keming Gao. (2017) The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 12:10, pages 1067-1081.
Read now
Read now
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Tae-Youn Jun, Ashwin A. Patkar, Prakash S. Masand & Chi-Un Pae. (2017) Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 26:6, pages 687-698.
Read now
Read now
Fang Fang, Zuowei Wang, Renrong Wu, Joseph R. Calabrese & Keming Gao. (2017) Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder?. Expert Review of Neurotherapeutics 17:4, pages 407-418.
Read now
Read now
Robert E. Davis & Christoph U. Correll. (2016) ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Review of Neurotherapeutics 16:6, pages 601-614.
Read now
Read now
Ricardo P. Garay, Leslie Citrome, Ludovic Samalin, Chen-Chung Liu, Morten S. Thomsen, Christoph U. Correll, Ahcène Hameg & Pierre-Michel Llorca. (2016) Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion on Pharmacotherapy 17:7, pages 921-936.
Read now
Read now
Mathias Zink & Christoph U Correll. (2015) Glutamatergic agents for schizophrenia: current evidence and perspectives. Expert Review of Clinical Pharmacology 8:3, pages 335-352.
Read now
Read now
Articles from other publishers (28)
Xiujun Zhang, Muhammad Jawwad Saif, Nazeran Idrees, Salma Kanwal, Saima Parveen & Fatima Saeed. (2023) QSPR Analysis of Drugs for Treatment of Schizophrenia Using Topological Indices. ACS Omega 8:44, pages 41417-41426.
Crossref
Crossref
Nimra Mumtaz & Muhammad Omair Hassan. 2023. Cognizance of Schizophrenia:: A Profound Insight into the Psyche. Cognizance of Schizophrenia:: A Profound Insight into the Psyche
127
147
.
K. Y. Kalitin, A. A. Spasov, O. Y. Mukha, G. V. Pridvorov & V. A. Lipatov. (2022) Pharmacological Targets and Mechanisms of Action of Antipsychotic Substances in the Context of the Neurochemical Theory of the Pathogenesis of Schizophrenia. Neuroscience and Behavioral Physiology 52:1, pages 108-123.
Crossref
Crossref
Carolyn Nicole Brown, Sarah G. Cook, Hillary F. Allen, Kevin C. Crosby, Tarjinder Singh, Steven J. Coultrap & K. Ulrich Bayer. (2021) Characterization of six CaMKIIα variants found in patients with schizophrenia. iScience 24:10, pages 103184.
Crossref
Crossref
Amber N. Edinoff, Prithvi K. Doppalapudi, Claudia Orellana, Caroline Ochoa, Shelby Patti, Yahya Ghaffar, Elyse M. Cornett, Aaron J. Kaye, Omar Viswanath, Ivan Urits, Adam M. Kaye & Alan D. Kaye. (2021) Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review. Frontiers in Psychiatry 12.
Crossref
Crossref
Tim J. Fyfe, Peter J. Scammells, J. Robert Lane & Ben Capuano. (2021) Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor. Molecules 26:13, pages 3799.
Crossref
Crossref
Donald J. AbrahamSeth Ablordeppey & Edward Ofori. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
69
.
Michael J. Majcher, Ali Babar, Andrew Lofts, Ashlyn Leung, Xiaoyun Li, Fahed Abu-Hijleh, Niels M.B. Smeets, Ram K. Mishra & Todd Hoare. (2021) In situ-gelling starch nanoparticle (SNP)/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide. Journal of Controlled Release 330, pages 738-752.
Crossref
Crossref
Yidan Sun, Wei Zhou, Luan Chen, Cong Huai, Hailiang Huang, Lin He & Shengying Qin. (2019) Omics in schizophrenia: current progress and future directions of antipsychotic treatments. Journal of Bio-X Research 2:4, pages 145-152.
Crossref
Crossref
Yu Xue, Xiaomeng He, Taoyi Yang, Yuxi Wang, Zhenming Liu, Guisen Zhang, Yanxing Wang, Kewei Wang, Liangren Zhang & Lihe Zhang. (2019) Discovery of fused heterocyclic carboxamide derivatives as novel α7-nAChR agonists: Synthesis, preliminary SAR and biological evaluation. European Journal of Medicinal Chemistry 182, pages 111618.
Crossref
Crossref
Marlene Jacobson, Wayne Childers & Magid Abou‐Gharbia. 2019. Successful Drug Discovery. Successful Drug Discovery
83
130
.
Amanda Krogmann, Luisa Peters, Laura von Hardenberg, Katja Bödeker, Viktor B. Nöhles & Christoph U. Correll. (2019) Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectrums 24:S1, pages 38-69.
Crossref
Crossref
Patrice Voss, Maryse E. Thomas, Gerson D. Guercio & Etienne de Villers-Sidani. (2019) Dysregulation of auditory neuroplasticity in schizophrenia. Schizophrenia Research 207, pages 3-11.
Crossref
Crossref
Peter M. Haddad & Christoph U. Correll. (2018) The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Therapeutic Advances in Psychopharmacology 8:11, pages 303-318.
Crossref
Crossref
Brendon Stubbs, Davy Vancampfort, Mats Hallgren, Joseph Firth, Nicola Veronese, Marco Solmi, Serge Brand, Joachim Cordes, Berend Malchow, Markus Gerber, Andrea Schmitt, Christoph U. Correll, Marc De Hert, Fiona Gaughran, Frank Schneider, Florence Kinnafick, Peter Falkai, Hans-Jürgen Möller & Kai G. Kahl. (2018) EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). European Psychiatry 54, pages 124-144.
Crossref
Crossref
Marc Cantillon, Robert Ings, Arul Prakash & Laxminarayan Bhat. (2018) A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. European Journal of Drug Metabolism and Pharmacokinetics 43:5, pages 573-585.
Crossref
Crossref
Brian Kirkpatrick, Jay B. Saoud, Gregory P. Strauss, Anthony O. Ahmed, Kazunori Tatsumi, Mark Opler, Remy Luthringer & Michael Davidson. (2018) The brief negative symptom scale (BNSS): Sensitivity to treatment effects. Schizophrenia Research 197, pages 269-273.
Crossref
Crossref
B. Galling, J. A. Vernon, A. K. Pagsberg, A. Wadhwa, E. Grudnikoff, A. J. Seidman, M. Tsoy-Podosenin, M. Poyurovsky, J. M. Kane & C. U. Correll. (2018) Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatrica Scandinavica 137:3, pages 187-205.
Crossref
Crossref
Marc Cantillon, Arul Prakash, Ajay Alexander, Robert Ings, Dennis Sweitzer & Laxminarayan Bhat. (2017) Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. Schizophrenia Research 189, pages 126-133.
Crossref
Crossref
Lakshmi Rajagopal, Sunoh Kwon, Mei Huang, Eric Michael, Laxminarayan Bhat, Marc Cantillon & Herbert Y. Meltzer. (2017) RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. Behavioural Brain Research 332, pages 180-199.
Crossref
Crossref
Inga Meyhöfer, Veena Kumari, Antje Hill, Nadine Petrovsky & Ulrich Ettinger. (2016) Sleep deprivation as an experimental model system for psychosis: Effects on smooth pursuit, prosaccades, and antisaccades. Journal of Psychopharmacology 31:4, pages 418-433.
Crossref
Crossref
Xin Chen, John D. McCorvy, Matthew G. Fischer, Kyle V. Butler, Yudao Shen, Bryan L. Roth & Jian Jin. (2016) Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists. Journal of Medicinal Chemistry 59:23, pages 10601-10618.
Crossref
Crossref
Claudia Mehler-Wex, Manfred Gerlach & Benno Schimmelmann. 2016. Neuro-/Psychopharmaka im Kindes- und Jugendalter. Neuro-/Psychopharmaka im Kindes- und Jugendalter
187
246
.
Ralph Aquila & Leslie Citrome. (2015) Cognitive impairment in schizophrenia: the great unmet need. CNS Spectrums 20:S1, pages 32-40.
Crossref
Crossref
René S. Kahn, Iris E. Sommer, Robin M. Murray, Andreas Meyer-Lindenberg, Daniel R. Weinberger, Tyrone D. Cannon, Michael O'Donovan, Christoph U. Correll, John M. Kane, Jim van Os & Thomas R. Insel. (2015) Schizophrenia. Nature Reviews Disease Primers 1:1.
Crossref
Crossref
P. Manu, L. Dima, M. Shulman, D. Vancampfort, M. De Hert & C. U. Correll. (2015) Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatrica Scandinavica 132:2, pages 97-108.
Crossref
Crossref
Z. Whitney, R. M. Procyshyn, D. H. Fredrikson & A. M. Barr. (2015) Treatment of clozapine-associated weight gain: a systematic review. European Journal of Clinical Pharmacology 71:4, pages 389-401.
Crossref
Crossref
Maren Carbon & Christoph U. Correll. (2014) Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectrums 19:S1, pages 35-53.
Crossref
Crossref